Market Cap
$600.2M
CRMD
CorMedix Inc.
$7.22 ▼ -2.76%
Prev close $7.42Market cap$600.2M
ConsensusStrong Buy
12-mo target$15.33 (+112.5%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)17 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CRMD right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$245.4M
Inst. Activity
17 buys / 11 sells
Social Sentiment
14° Bearish
SEC Reports
9
Press Releases
3
Price chart 30d -16.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 Insider
Dillione Janet acquired via exercise 48,909 shares
Director
Aug 29, 2026 Insider
Hurlburt Elizabeth surrendered for taxes 8,076 shares
Chief Operating Officer @ $8.30 ($67.0K)
Aug 29, 2026 Insider
Blum Susan surrendered for taxes 8,424 shares
Chief Financial Officer @ $8.30 ($69.9K)
Aug 17, 2026 short_volume
Aug 13, 2026 SEC Short Volume: CRMD — 62.4% short (0.6M / 1.0M)
Short: 635,922 | Exempt: 200 | TRF Vol: 1,019,234 | Short Ratio: 62.4% | Off-exchange volume (dark p
No summary provided
PRESS-RELEASE — Impact 5/10
CorMedix reported Q2 2026 consolidated revenue of $101.9M and net income of $26.0M ($0.33 basic EPS), compared to $39.7M
8-K — Impact 5/10
CorMedix Inc. dismissed its independent auditor CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY) as its new independe
8-K — Impact 4/10
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — ADD
779,535 shares ($6.1M)
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Aug 14, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Apr 28, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Apr 28, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Apr 27, 2026 | Needham | MAINTAIN | Buy | 50% |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Aug 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% |
Price targets
Where 6 covering analysts think CRMD trades over the next 12 months.
$15.33 +112.5% upside Strong Buy
Current$7.22 Low$13.00 Median$15.00 High$19.00 6 analysts
$13.00$19.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Social media sentiment mood -27.5%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
14°
Bearish
BearishNeutralBullish
Recent posts
If you missed on Moderna $MRNA +150%, don’t miss CorMedix $CRMD - 1X - 2X setup
▲ 1 · 💬 0· ⚡ 0.5
If you missed on Moderna $MRNA +150%, Don’t Miss CorMedix $CRMD — 1X -2X setup
▲ 1 · 💬 0· ⚡ 0.5
If you missed on Moderna $MRNA +150%, Don’t Miss CorMedix $CRMD — 1X -2X setup
▲ 1 · 💬 0· ⚡ 0.5
If You Missed Moderna $MRNA +150%, Don’t Miss CorMedix $CRMD — 1X–2X Setup
▲ 1 · 💬 0· ⚡ 0.5
If You Missed Moderna $MRNA +150%, Don’t Miss CorMedix $CRMD — 1X–2X Setup
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 6 bullish, 0 bearish, 0 mixed, 3 neutral · avg impact 6.4/10.Plus 3 press releases.
NEUTRALPRESS-RELEASE5/10
No summary provided
Aug 13, 2026
NEUTRAL8-K5/10
CorMedix reported Q2 2026 consolidated revenue of $101.9M and net income of $26.0M ($0.33 basic EPS)
Aug 13, 2026
NEUTRAL8-K4/10
CorMedix Inc. dismissed its independent auditor CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY)
Jul 1, 2026
BULLISHINST-CLUSTER7/10
A strong institutional cluster formed in CRMD during Q4 2024, with 8 buyers (net +$14.6M) overwhelmi
Jun 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 17, 2026
short_volume
Short Volume: CRMD — 62.4% short (0.6M / 1.0M)
Short: 635,922 | Exempt: 200 | TRF Vol: 1,019,234 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Aug 14, 2026
short_volume
Short Volume: CRMD — 71.7% short (0.9M / 1.2M)
Short: 876,892 | Exempt: 2,622 | TRF Vol: 1,223,700 | Short Ratio: 71.7% | Off-exchange volume (dark pool + OTC)
Aug 13, 2026
earnings
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒
Aug 13, 2026
earnings_calendar
CRMD Q2 2026 Earnings Scheduled — 2026-08-13
Aug 12, 2026
short_volume
Short Volume: CRMD — 81.6% short (0.4M / 0.5M)
Short: 415,288 | Exempt: 710 | TRF Vol: 508,837 | Short Ratio: 81.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.11 | $-0.17–$-0.05 | -108.5% | -2.6% | 1↑ 2↓ | $0.1B | 6 |
| Next Q | $-0.13 | $-0.22–$-0.06 | -181.3% | +1.5% | 0↑ 2↓ | $0.1B | 6 |
| Current FY | $0.49 | $0.36–$0.59 | -75.7% | +1.4% | 2↑ 3↓ | $0.3B | 6 |
| Next FY | $0.06 | $-0.16–$0.23 | -88.5% | -5.5% | — | $0.3B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.107 | — |
| 7d ago | $-0.104 | -0.003 |
| 30d ago | $-0.104 | -0.003 |
| 60d ago | $-0.094 | -0.013 |
| 90d ago | $-0.094 | -0.013 |
Institutional ownership
Which big funds own CRMD (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $245.4M total value (31,256,823 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 17 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 6,324,111 | $49.6M | 20.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,135,075 | $24.6M | 10.0% | — |
| STATE STREET CORP | 2,316,845 | $18.2M | 7.4% | — |
| ROYCE & ASSOCIATES LP | 2,176,362 | $17.1M | 7.0% | DOUBLED +679.9% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,947,014 | $15.3M | 6.2% | — |
| UBS Group AG | 1,877,940 | $14.7M | 6.0% | DOUBLED +141.8% |
| Alyeska Investment Group, L.P. | 850,000 | $6.7M | 2.7% | — |
| MARSHALL WACE, LLP | 779,535 | $6.1M | 2.5% | ADD +55.0% |
| NORTHERN TRUST CORP | 756,430 | $5.9M | 2.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 708,604 | $5.6M | 2.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP | ADD | 502,965 | 779,535 | +55.0% | $6.1M |
| RAYMOND JAMES FINANCIAL INC | ADD | 328,224 | 446,142 | +35.9% | $3.5M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | 26,402 | 345,341 | +1208.0% | $2.7M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 153,510 | 318,968 | +107.8% | $2.5M |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 499,803 | 211,622 | -57.7% | $1.7M |
| Squarepoint Ops LLC | TRIM | 285,070 | 207,378 | -27.3% | $1.6M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 171,882 | 113,740 | -33.8% | $892.9K |
| DEUTSCHE BANK AG\ | ADD | 61,074 | 77,383 | +26.7% | $607.5K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 32,498 | 68,996 | +112.3% | $541.6K |
| CITIGROUP INC | ADD | 38,151 | 66,228 | +73.6% | $519.9K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 7 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Dillione Janet | Director | EXERCISE | 48,909 | — | — |
| Aug 29, 2026 | Hurlburt Elizabeth | Chief Operating Officer | TAX W/H | 8,076 | $8.30 | $67.0K |
| Aug 29, 2026 | Blum Susan | Chief Financial Officer | TAX W/H | 8,424 | $8.30 | $69.9K |
| Aug 29, 2026 | Zelnick Kaufman Beth | Chief Legal Officer | TAX W/H | 8,424 | $8.30 | $69.9K |
| Feb 4, 2026 | Hurlburt Elizabeth | Chief Operating Officer | AWARD | 36,006 | — | — |
| Feb 4, 2026 | Todisco Joseph | Chief Executive Officer | AWARD | 77,156 | — | — |
| Feb 4, 2026 | Zelnick Kaufman Beth | Chief Legal Officer | AWARD | 36,006 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CRMD.
Shares short
16,202,272
Settlement Sep 15, 2026
Change vs prior
+1.1%
Semi-monthly cycle
Days to cover
18.5
At avg daily volume
Of shares outstanding
≈20.8%
Estimate — not % of float
All CRMD filing & press-release reports (12)
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- 8-K reportJul 1, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportJun 8, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026